Screener / SEC EDGAR /CIK 0001515673 /10-K filed Feb 18, 2026, compared with Feb 19, 2025 /Numbers from the XBRL of the 10-Ks
Nasdaq Health care · Pharmaceuticals

Ultragenyx Pharmaceutical Inc. RARE

Compare with peers Embed
Planned sales, announced before they happen

5 trading plans running, 16 Form 144 notices for $1.5M

10-Q, 10-K and Form 144
Plans running now 5 Howard Horn, Theodore Huizenga, John Pinion, Karah Parschauer, Matthew Fust
Plans adopted 25 reported since May 5, 2023 Form 144 notices 16 $1.5M the sellers expected to sell

What RARE's directors and officers said they would sell, before they sold: trading plans the company reports each quarter, and the Form 144 notices sellers file on the day of a planned sale. Most of these sales are routine, such as selling shares from vesting stock awards.

Plans adopted or ended

Trading plans · XBRL, 10-Q and 10-K

From Mar 11, 2025 to Jun 4, 2027. The thin line is today; a filled bar is a plan still running, a paler one has ended or expired. The ten newest plans are drawn; all are in the table.

InsiderWhatDateReported in
Howard Horn
Executive Vice President, Chief Financial Officer, Corporate Strategy
Adopted 10b5-1 plan Jun 5, 2026 10-Q Aug 5, 2026
Theodore Huizenga
Senior Vice President and Chief Accounting Officer
Adopted 10b5-1 plan Jun 4, 2026 10-Q Aug 5, 2026
John Pinion
EVP, Chief Quality Officer and Translational Sciences
Adopted 10b5-1 plan May 19, 2026 10-Q Aug 5, 2026
Karah Parschauer
Executive Vice President, Chief Legal Officer and Corporate Affairs
Adopted 10b5-1 plan Mar 16, 2026 10-Q May 6, 2026
Matthew Fust
Director
Adopted 10b5-1 plan Mar 16, 2026 10-Q May 6, 2026
Eric Crombez
Chief Medical Officer
Adopted 10b5-1 plan Sep 5, 2025 10-Q Nov 5, 2025
Howard Horn
Chief Financial Officer and EVP, Corporate Strategy
Adopted 10b5-1 plan Sep 2, 2025 10-Q Nov 5, 2025
John Pinion
Translational Research and Chief Quality Officer
Adopted 10b5-1 plan May 9, 2025 10-Q Aug 6, 2025
Emil D. Kakkis
President and CEO, Director
Adopted 10b5-1 plan Mar 14, 2025 10-Q May 7, 2025
Karah Parschauer
Chief Legal Officer and Corporate Affairs
Adopted 10b5-1 plan Mar 11, 2025 10-Q May 7, 2025
Howard Horn
Chief Financial Officer
Adopted 10b5-1 plan Dec 9, 2024 10-K Feb 19, 2025
Eric Crombez
Chief Medical Officer
Adopted 10b5-1 plan Dec 3, 2024 10-K Feb 19, 2025
Matthew Fust
Board Member
Adopted 10b5-1 plan Nov 22, 2024 10-K Feb 19, 2025
Corsee Sanders
Board Member
Adopted 10b5-1 plan Nov 15, 2024 10-K Feb 19, 2025
Shehnaaz Suliman
Board Member
Adopted 10b5-1 plan Nov 8, 2024 10-Q Aug 6, 2025
Shehnaaz Suliman
Board Member
Adopted 10b5-1 plan Nov 8, 2024 10-K Feb 19, 2025
Dennis Huang
Chief Technical Operations Officer, Gene Therapy Research & Development
Adopted 10b5-1 plan May 7, 2024 10-Q Aug 2, 2024
John Pinion
Chief Quality Operations Officer and EVP, Translational Sciences
Adopted 10b5-1 plan May 7, 2024 10-Q Aug 2, 2024
Eric Crombez
EVP, Chief Medical Officer
Adopted 10b5-1 plan Mar 11, 2024 10-Q May 3, 2024
Shehnaaz Suliman
Board Member
Adopted 10b5-1 plan Mar 8, 2024 10-Q May 3, 2024
Karah Parschauer
EVP, Chief Legal Officer and Corporate Affairs
Adopted 10b5-1 plan Mar 5, 2024 10-Q May 3, 2024
Emil Kakkis
EVP, Chief Executive Officer and Director
Adopted 10b5-1 plan Mar 1, 2024 10-Q May 3, 2024
Matthew Fust
member of the Company’s Board of Directors
Adopted 10b5-1 plan Dec 7, 2023 10-K Feb 21, 2024
Corsee Sanders
member of the Company’s Board of Directors
Adopted 10b5-1 plan Nov 10, 2023 10-K Feb 21, 2024
Shehnaaz Suliman
Board Member
Adopted 10b5-1 plan – 10-Q Nov 5, 2025
Show the other 17 plans

From the XBRL of the company's 10-Qs and 10-Ks (Regulation S-K Item 408, reported since 2023): 15 filings checked since May 5, 2023.

Notices of planned sales

Form 144 · Form 144 XML, SEC

What the sellers expected to sell on the Form 144 notices filed each month (the value on the notice).

FiledSellerSharesValue
Sep 15, 2026 THEODORE HUIZENGA
Officer
1,283 $17K
Aug 3, 2026 HOWARD HORN
Officer
4,696 $117K
Jul 1, 2026 HOWARD HORN
Officer
4,698 $156K
Jun 15, 2026 KARAH PARSCHAUER
Officer
3,799 $93K
Jun 15, 2026 CORAZON D. SANDERS
Director
2,000 $50K
Jun 1, 2026 HOWARD HORN
Officer
4,653 $111K
May 18, 2026 SHEHNAAZ SULIMAN
Director
5,740 $144K
May 1, 2026 HOWARD HORN
Officer
4,683 $117K
Apr 1, 2026 HOWARD HORN
Officer
4,683 $98K
Mar 10, 2026 KARAH PARSCHAUER
Officer
3,508 $80K
Mar 6, 2026 KARAH PARSCHAUER
Officer
6,018 $129K
Mar 3, 2026 HOWARD HORN
Officer
1,635 $37K
Mar 2, 2026 HOWARD HORN
Officer
3,119 $70K
Feb 2, 2026 HOWARD HORN
Officer
3,061 $72K
Jan 2, 2026 HOWARD HORN
Officer
3,150 $72K
Dec 10, 2025 HOWARD HORN
Officer
3,081 $112K
Show the other 8 notices

From the Form 144 XML filed with the SEC, since Dec 10, 2025. The value is the seller's estimate on the notice. "Form 4 sales after" matches the seller's Form 4 sales in the 30 days after the notice, by name; Form 4s go back 180 days.

Sources

Regulation S-K Item 408 in the XBRL of each 10-Q and 10-K (since 2023); the Form 144 XML at the SEC.

Also

Insider trades: the Form 4s for the sales these plans led to.

Work with it

Excel workbook · CSV. Google Sheet that stays up to date: paste =IMPORTDATA("https://tickdelta.com/company/RARE/export.csv") into a cell.

Next:Owners
Esc

Type a ticker such as AAPL, a name, an investor such as Buffett, or a topic such as tariffs. ↑ ↓ to move, Enter to open.